The key factors contributing to the risk, diagnosis and treatment of non-tuberculous mycobacterial opportunistic infections

[1]Falkinham J.O. 3rd: Environmental sources of nontuberculous mycobacteria. Clin. Chest Med., 2015; 36: 35-41 Falkinham J.O Environmental sources of nontuberculous mycobacteria Clin. Chest Med 2015 36 35 4110.1016/j.ccm.2014.10.003Search in Google Scholar

[2]Turenne C.Y.: Nontuberculous mycobacteria: Insights on taxonomy and evolution. Infect. Genet. Evol., 2019; 72: 159-168 Turenne C.Y. Nontuberculous mycobacteria: Insights on taxonomy and evolution Infect. Genet. Evol 2019 72 159 16810.1016/j.meegid.2019.01.017Search in Google Scholar

[3]Runyon E.H.: Anonymous mycobacteria in pulmonary disease. Med. Clin. North Am., 1959; 43: 273-290 Runyon E.H. Anonymous mycobacteria in pulmonary disease Med. Clin. North Am 1959 43 273 29010.1016/S0025-7125(16)34193-1Search in Google Scholar

[4]Pereira A.C., Ramos B., Reis A.C., Cunha M.V.: Non-tuberculous mycobacteria: Molecular and physiological bases of virulence and adaptation to ecological niches. Microorganisms, 2020; 8: 1380 Pereira A.C. Ramos B. Reis A.C. Cunha M.V. Non-tuberculous mycobacteria: Molecular and physiological bases of virulence and adaptation to ecological niches Microorganisms 2020 8 138010.3390/microorganisms8091380756344232916931Search in Google Scholar

[5]Aung T.T., Beuerman R.W.: Atypical mycobacterial keratitis: A Negligent and emerging thread for blindness. J. Rare Dis. Res. Treat., 2018; 3: 15-20 Aung T.T. Beuerman R.W. Atypical mycobacterial keratitis: A Negligent and emerging thread for blindness J. Rare Dis. Res. Treat 2018 3 15 2010.29245/2572-9411/2018/1.1143Search in Google Scholar

[6]Piersimoni C., Scarparo C.: Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg. Infect. Dis., 2009; 15: 1351-1358 Piersimoni C. Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons Emerg. Infect. Dis 2009 15 1351 135810.3201/eid1509.081259281985219788801Search in Google Scholar

[7]Prevots D.R., Marras T.K.: Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review. Clin. Chest Med., 2015; 36: 13-34 Prevots D.R. Marras T.K. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: A review Clin. Chest Med 2015 36 13 3410.1016/j.ccm.2014.10.002433256425676516Search in Google Scholar

[8]Baldwin S.L., Larsen S.E., Ordway D., Cassell G., Coler R.N.: The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases. PLoS Negl. Trop. Dis., 2019; 13: e0007083 Baldwin S.L. Larsen S.E. Ordway D. Cassell G. Coler R.N. The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases PLoS Negl. Trop. Dis 2019 13 e000708310.1371/journal.pntd.0007083637557230763316Search in Google Scholar

[9]Bi S., Hu F.S., Yu H.Y., Xu K.J., Zheng B.W., Ji Z.K., Li J.J., Deng M., Hu H.Y., Sheng J.F.: Nontuberculous mycobacterial osteomyelitis. Infect. Dis., 2015; 47: 673-685 Bi S. Hu F.S. Yu H.Y. Xu K.J. Zheng B.W. Ji Z.K. Li J.J. Deng M. Hu H.Y. Sheng J.F. Nontuberculous mycobacterial osteomyelitis Infect. Dis 2015 47 673 68510.3109/23744235.2015.1040445471413225915177Search in Google Scholar

[10]Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., Holland S.M., Horsburgh R., Huitt G., Iademarco M.F., et al.: An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med., 2007; 175: 367-416 Griffith D.E. Aksamit T. Brown-Elliott B.A. Catanzaro A. Daley C. Gordin F. Holland S.M. Horsburgh R. Huitt G. Iademarco M.F. et al An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am. J. Respir. Crit. Care Med 2007 175 367 41610.1164/rccm.200604-571ST17277290Search in Google Scholar

[11]Wu M.L., Aziz D.B., Dartois V., Dick T.: NTM drug discovery: Status, gaps and the way forward. Drug Discov. Today, 2018; 23: 1502-1519 Wu M.L. Aziz D.B. Dartois V. Dick T. NTM drug discovery: Status, gaps and the way forward Drug Discov. Today 2018 23 1502 151910.1016/j.drudis.2018.04.001607881429635026Search in Google Scholar

[12]Nishiuchi Y., Iwamoto T., Maruyama F.: Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium Complex. Front. Med., 2017; 4: 27 Nishiuchi Y. Iwamoto T. Maruyama F. Infection sources of a common non-tuberculous mycobacterial pathogen, Mycobacterium avium Complex Front. Med 2017 4 2710.3389/fmed.2017.00027533963628326308Search in Google Scholar

[13]Burgess W., Margolis A., Gibbs S., Duarte R.S., Jackson M.: Disinfectant susceptibility profiling of glutaraldehyde-resistant nontuberculous mycobacteria. Infect. Control Hosp. Epidemiol., 2017; 38: 784-791 Burgess W. Margolis A. Gibbs S. Duarte R.S. Jackson M. Disinfectant susceptibility profiling of glutaraldehyde-resistant nontuberculous mycobacteria Infect. Control Hosp. Epidemiol 2017 38 784 79110.1017/ice.2017.75550761428462746Search in Google Scholar

[14]Moore J.E., Kruijshaar M.E., Ormerod L.P., Drobniewski F., Abubakar I.: Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006. BMC Public Health, 2010; 10: 612 Moore J.E. Kruijshaar M.E. Ormerod L.P. Drobniewski F. Abubakar I. Increasing reports of non-tuberculous mycobacteria in England, Wales and Northern Ireland, 1995-2006 BMC Public Health 2010 10 61210.1186/1471-2458-10-612296463120950421Search in Google Scholar

[15]Shah N.M., Davidson J.A., Anderson L.F., Lalor M.K., Kim J., Thomas H.L., Lipman M., Abubakar I.: Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012. BMC Infect. Dis., 2016; 16: 195 Shah N.M. Davidson J.A. Anderson L.F. Lalor M.K. Kim J. Thomas H.L. Lipman M. Abubakar I. Pulmonary Mycobacterium avium-intracellulare is the main driver of the rise in non-tuberculous mycobacteria incidence in England, Wales and Northern Ireland, 2007-2012 BMC Infect. Dis 2016 16 19510.1186/s12879-016-1521-3485892727154015Search in Google Scholar

[16]Andréjak C., Thomsen V.Ø., Johansen I.S., Riis A., Benfield T.L., Duhaut P., Sørensen H.T., Lescure F.X., Thomsen R.W.: Nontuberculous pulmonary mycobacteriosis in Denmark: Incidence and prognostic factors. Am. J. Respir. Crit. Care Med., 2010; 181: 514521 Andréjak C. Thomsen V.Ø. Johansen I.S. Riis A. Benfield T.L. Duhaut P. Sørensen H.T. Lescure F.X. Thomsen R.W. Nontuberculous pulmonary mycobacteriosis in Denmark: Incidence and prognostic factors Am. J. Respir. Crit. Care Med 2010 181 51452110.1164/rccm.200905-0778OC20007929Search in Google Scholar

[17]Diel R., Jacob J., Lampenius N., Loebinger M., Nienhaus A., Rabe K.F., Ringshausen F.C.: Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur. Respir. J., 2017; 49: 1602109 Diel R. Jacob J. Lampenius N. Loebinger M. Nienhaus A. Rabe K.F. Ringshausen F.C. Burden of non-tuberculous mycobacterial pulmonary disease in Germany Eur. Respir. J 2017 49 160210910.1183/13993003.02109-201628446559Search in Google Scholar

[18]Modrá H., Ulmann V., Caha J., Hübelová D., Konečný O., Svobodová J., Weston R.T., Pavlík I.: Socio-economic and environmental factors related to spatial differences in human non-tuberculous mycobacterial diseases in the Czech Republic. Int. J. Environ. Res. Public Health, 2019; 16: 3969 Modrá H. Ulmann V. Caha J. Hübelová D. Konečný O. Svobodová J. Weston R.T. Pavlík I. Socio-economic and environmental factors related to spatial differences in human non-tuberculous mycobacterial diseases in the Czech Republic Int. J. Environ. Res. Public Health 2019 16 396910.3390/ijerph16203969684354731627484Search in Google Scholar

[19]Truden S., Žolnir-Dovč M., Sodja E., Starčič Erjavec M.: Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: Frequency, clinical importance, and molecular and phenotypic resistance profiles. Infect. Genet. Evol., 2020; 82: 104311 Truden S. Žolnir-Dovč M. Sodja E. Starčič Erjavec M. Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: Frequency, clinical importance, and molecular and phenotypic resistance profiles Infect. Genet. Evol 2020 82 10431110.1016/j.meegid.2020.10431132247868Search in Google Scholar

[20]van der Werf M.J., Ködmön C., Katalinić-Janković V., Kummik T., Soini H., Richter E., Papaventsis D., Tortoli E., Perrin M., van Soolingen D., et al.: Inventory study of non-tuberculous mycobacteria in the European Union. BMC Infect. Dis., 2014; 14: 62 van der Werf M.J. Ködmön C. Katalinić-Janković V. Kummik T. Soini H. Richter E. Papaventsis D. Tortoli E. Perrin M. van Soolingen D. et al Inventory study of non-tuberculous mycobacteria in the European Union BMC Infect. Dis 2014 14 6210.1186/1471-2334-14-62392201224502462Search in Google Scholar

[21]Adjemian J., Daniel-Wayman S., Ricotta E., Prevots D.R.: Epidemiology of nontuberculous mycobacteriosis. Semin. Respir. Crit. Care Med., 2018; 39: 325-335 Adjemian J. Daniel-Wayman S. Ricotta E. Prevots D.R. Epidemiology of nontuberculous mycobacteriosis Semin. Respir. Crit. Care Med 2018 39 325 33510.1055/s-0038-165149130071547Search in Google Scholar

[22]Marras T.K., Campitelli M.A., Kwong J.C., Lu H., Brode S.K., Marchand-Austin A., Gershon A.S., Jamieson F.B.: Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease. Eur. Respir. J., 2016; 48: 928-931 Marras T.K. Campitelli M.A. Kwong J.C. Lu H. Brode S.K. Marchand-Austin A. Gershon A.S. Jamieson F.B. Risk of nontuberculous mycobacterial pulmonary disease with obstructive lung disease Eur. Respir. J 2016 48 928 93110.1183/13993003.00033-201627288038Search in Google Scholar

[23]Namkoong H., Kurashima A., Morimoto K., Hoshino Y., Hasegawa N., Ato M., Mitarai S.: Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg. Infect. Dis., 2016; 22: 1116-1117 Namkoong H. Kurashima A. Morimoto K. Hoshino Y. Hasegawa N. Ato M. Mitarai S. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan Emerg. Infect. Dis 2016 22 1116 111710.1183/1393003.congress-2017.OA1972Search in Google Scholar

[24]Martiniano S.L., Nick J.A., Daley C.L.: Nontuberculous mycobacterial infections in cystic fibrosis. Thorac. Surg. Clin., 2019; 29: 95-108 Martiniano S.L. Nick J.A. Daley C.L. Nontuberculous mycobacterial infections in cystic fibrosis Thorac. Surg. Clin 2019 29 95 10810.1016/j.thorsurg.2018.09.00830454926Search in Google Scholar

[25]Skolnik K., Kirkpatrick G., Quon B.S.: Nontuberculous mycobacteria in cystic fibrosis. Curr. Treat. Options Infect. Dis., 2016; 8: 259-274 Skolnik K. Kirkpatrick G. Quon B.S. Nontuberculous mycobacteria in cystic fibrosis Curr. Treat. Options Infect. Dis 2016 8 259 27410.1007/s40506-016-0092-6515501828035194Search in Google Scholar

[26]Ben Salah I., Cayrou C., Raoult D., Drancourt M.: Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., members of the Mycobacterium avium complex. Int. J. Syst. Evol. Microbiol., 2009; 59: 2803-2808 Ben Salah I. Cayrou C. Raoult D. Drancourt M. Mycobacterium marseillense sp. nov., Mycobacterium timonense sp. nov. and Mycobacterium bouchedurhonense sp. nov., members of the Mycobacterium avium complex Int. J. Syst. Evol. Microbiol 2009 59 2803 280810.1099/ijs.0.010637-019628609Search in Google Scholar

[27]Tortoli E., Rindi L., Garcia M.J., Chiaradonna P., Dei R., Garzelli C., Kroppenstedt R.M., Lari N., Mattei R., Mariottini A., et al.: Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov. Int. J. Syst. Evol. Microbiol., 2004; 54: 1277-1285 Tortoli E. Rindi L. Garcia M.J. Chiaradonna P. Dei R. Garzelli C. Kroppenstedt R.M. Lari N. Mattei R. Mariottini A. et al Proposal to elevate the genetic variant MAC-A, included in the Mycobacterium avium complex, to species rank as Mycobacterium chimaera sp. nov Int. J. Syst. Evol. Microbiol 2004 54 1277 128510.1099/ijs.0.02777-015280303Search in Google Scholar

[28]Hoefsloot W., van Ingen J., Andrejak C., Angeby K., Bauriaud R., Bemer P., Beylis N., Boeree M.J., Cacho J., Chihota V., et al.: The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: An NTM-NET collaborative study. Eur. Respir. J., 2013; 42: 1604-1613 Hoefsloot W. van Ingen J. Andrejak C. Angeby K. Bauriaud R. Bemer P. Beylis N. Boeree M.J. Cacho J. Chihota V. et al The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: An NTM-NET collaborative study Eur. Respir. J 2013 42 1604 161310.1183/09031936.0014921223598956Search in Google Scholar

[29]Kwiatkowska S., Augustynowicz-Kopeć E., Korzeniewska-Koseła M., Filipczak D., Gruszczyński P., Zabost A., Klatt M., Sadkowska-Todys M.: Nontuberculous mycobacteria strains isolated from patients between 2013 and 2017 in Poland. Our data with respect to the global trends. Adv. Respir. Med., 2018; 86: 291-298 Kwiatkowska S. Augustynowicz-Kopeć E. Korzeniewska-Koseła M. Filipczak D. Gruszczyński P. Zabost A. Klatt M. Sadkowska-Todys M. Nontuberculous mycobacteria strains isolated from patients between 2013 and 2017 in Poland. Our data with respect to the global trends Adv. Respir. Med 2018 86 291 29810.5603/ARM.a2018.004730594996Search in Google Scholar

[30]Gupta R.S., Lo B., Son J.: Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera. Front. Microbiol., 2018; 9: 67 Gupta R.S. Lo B. Son J. Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera Front. Microbiol 2018 9 6710.3389/fmicb.2018.00067581956829497402Search in Google Scholar

[31]Tortoli E., Kohl T.A., Brown-Elliott B.A., Trovato A., Leão S.C., Garcia M.J., Vasireddy S., Turenne C.Y., Griffith D.E., Philley J.V., et al.: Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov. Int. J. Syst. Evol. Microbiol., 2016; 66: 4471-4479 Tortoli E. Kohl T.A. Brown-Elliott B.A. Trovato A. Leão S.C. Garcia M.J. Vasireddy S. Turenne C.Y. Griffith D.E. Philley J.V. et al Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov Int. J. Syst. Evol. Microbiol 2016 66 4471 447910.1099/ijsem.0.00137627499141Search in Google Scholar

[32]Tai A.Y., Athan E., Friedman N.D., Hughes A., Walton A., O’Brien D.P.: Increased severity and spread of Mycobacterium ulcerans, Southeastern Australia. Emerg. Infect. Dis., 2018; 24: 58-64 Tai A.Y. Athan E. Friedman N.D. Hughes A. Walton A. O’Brien D.P. Increased severity and spread of Mycobacterium ulcerans, Southeastern Australia Emerg. Infect. Dis 2018 24 58 6410.3201/eid2401.171070574946528980523Search in Google Scholar

[33]Slany M., Jezek P., Bodnarova M.: Fish tank granuloma caused by Mycobacterium marinum in two aquarists: Two case reports. Biomed. Res. Int., 2013; 2013: 161329 Slany M. Jezek P. Bodnarova M. Fish tank granuloma caused by Mycobacterium marinum in two aquarists: Two case reports Biomed. Res. Int 2013 2013 16132910.1155/2013/161329Search in Google Scholar

[34]Lindeboom J.A., Bruijnesteijn van Coppenraet L.E., van Soolingen D., Prins J.M., Kuijper E.J.: Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin. Microbiol. Rev., 2011; 24: 701-717 Lindeboom J.A. Bruijnesteijn van Coppenraet L.E. van Soolingen D. Prins J.M. Kuijper E.J. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections Clin. Microbiol. Rev 2011 24 701 71710.1128/CMR.00020-11319482521976605Search in Google Scholar

[35]Honda J.R., Knight V., Chan E.D.: Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin. Chest Med., 2015; 36: 1-11 Honda J.R. Knight V. Chan E.D. Pathogenesis and risk factors for nontuberculous mycobacterial lung disease Clin. Chest Med 2015 36 1 1110.1016/j.ccm.2014.10.00125676515Search in Google Scholar

[36]Lai C.C., Lee L.N., Ding L.W., Yu C.J., Hsueh P.R., Yang P.C.: Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan. J. Infect., 2006; 53: 77-84 Lai C.C. Lee L.N. Ding L.W. Yu C.J. Hsueh P.R. Yang P.C. Emergence of disseminated infections due to nontuberculous mycobacteria in non-HIV-infected patients, including immunocompetent and immunocompromised patients in a university hospital in Taiwan J. Infect 2006 53 77 8410.1016/j.jinf.2005.10.00916313964Search in Google Scholar

[37]Feazel L.M., Baumgartner L.K., Peterson K.L., Frank D.N., Harris J.K., Pace N.R.: Opportunistic pathogens enriched in showerhead biofilms. Proc. Natl. Acad. Sci. USA, 2009; 106: 16393-16399 Feazel L.M. Baumgartner L.K. Peterson K.L. Frank D.N. Harris J.K. Pace N.R. Opportunistic pathogens enriched in showerhead biofilms Proc. Natl. Acad. Sci. USA 2009 106 16393 1639910.1073/pnas.0908446106275252819805310Search in Google Scholar

[38]Thomson R., Tolson C., Carter R., Coulter C., Huygens F., Hargreaves M.: Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM. J. Clin. Microbiol., 2013; 51: 3006-3011 Thomson R. Tolson C. Carter R. Coulter C. Huygens F. Hargreaves M. Isolation of nontuberculous mycobacteria (NTM) from household water and shower aerosols in patients with pulmonary disease caused by NTM J. Clin. Microbiol 2013 51 3006 301110.1128/JCM.00899-13375468023843489Search in Google Scholar

[39]Thomas V., McDonnell G.: Relationship between mycobacteria and amoebae: Ecological and epidemiological concerns. Lett. Appl. Microbiol., 2007; 45: 349-357 Thomas V. McDonnell G. Relationship between mycobacteria and amoebae: Ecological and epidemiological concerns Lett. Appl. Microbiol 2007 45 349 35710.1111/j.1472-765X.2007.02206.x17897376Search in Google Scholar

[40]Drancourt M.: Looking in amoebae as a source of mycobacteria. Microb. Pathog., 2014; 77: 119-124 Drancourt M. Looking in amoebae as a source of mycobacteria Microb. Pathog 2014 77 119 12410.1016/j.micpath.2014.07.00125017516Search in Google Scholar

[41]Yu H.S., Jeong H.J., Hong Y.C., Seol S.Y., Chung D.I., Kong H.H.: Natural occurrence of Mycobacterium as an endosymbiont of Acanthamoeba isolated from a contact lens storage case. Korean J. Parasitol., 2007; 45: 11-18 Yu H.S. Jeong H.J. Hong Y.C. Seol S.Y. Chung D.I. Kong H.H. Natural occurrence of Mycobacterium as an endosymbiont of Acanthamoeba isolated from a contact lens storage case Korean J. Parasitol 2007 45 11 1810.3347/kjp.2007.45.1.11252634017374973Search in Google Scholar

[42]Marsollier L., Robert R., Aubry J., Saint André J.P., Kouakou H., Legras P., Manceau A.L., Mahaza C., Carbonnelle B.: Aquatic insects as a vector for Mycobacterium ulcerans. Appl. Environ. Microbiol., 2002; 68: 4623-4628 Marsollier L. Robert R. Aubry J. Saint André J.P. Kouakou H. Legras P. Manceau A.L. Mahaza C. Carbonnelle B. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ. Microbiol 2002 68 4623 462810.1128/AEM.68.9.4623-4628.200212408512200321Search in Google Scholar

[43]Eltholth M.M., Marsh V.R., Van Winden S., Guitian F.J.: Contamination of food products with Mycobacterium avium paratuberculosis A systematic review. J. Appl. Microbiol., 2009; 107: 1061-1071 Eltholth M.M. Marsh V.R. Van Winden S. Guitian F.J. Contamination of food products with Mycobacterium avium paratuberculosis A systematic review J. Appl. Microbiol 2009 107 1061 107110.1111/j.1365-2672.2009.04286.x19486426Search in Google Scholar

[44]Shankar H., Singh S.V., Singh P.K., Singh A.V., Sohal J.S., Greenstein R.J.: Presence, characterization, and genotype profiles of Mycobacterium avium subspecies paratuberculosis from unpasteurized individual and pooled milk, commercial pasteurized milk, and milk products in India by culture, PCR, and PCR-REA methods. Int. J. Infect. Dis., 2010; 14: e121-e126 Shankar H. Singh S.V. Singh P.K. Singh A.V. Sohal J.S. Greenstein R.J. Presence, characterization, and genotype profiles of Mycobacterium avium subspecies paratuberculosis from unpasteurized individual and pooled milk, commercial pasteurized milk, and milk products in India by culture, PCR, and PCR-REA methods Int. J. Infect. Dis 2010 14 e121 e12610.1016/j.ijid.2009.03.03119576834Search in Google Scholar

[45]Mougari F., Guglielmetti L., Raskine L., Sermet-Gaudelus I., Veziris N., Cambau E.: Infections caused by Mycobacterium abscessus : Epidemiology, diagnostic tools and treatment. Expert Rev. Anti Infect. Ther., 2016; 14: 1139-1154 Mougari F. Guglielmetti L. Raskine L. Sermet-Gaudelus I. Veziris N. Cambau E. Infections caused by Mycobacterium abscessus : Epidemiology, diagnostic tools and treatment Expert Rev. Anti Infect. Ther 2016 14 1139 115410.1080/14787210.2016.123830427690688Search in Google Scholar

[46]Bryant J.M., Grogono D.M., Rodriguez-Rincon D., Everall I., Brown K.P., Moreno P., Verma D., Hill E., Drijkoningen J., Gilligan P., et al.: Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016; 354: 751-757 Bryant J.M. Grogono D.M. Rodriguez-Rincon D. Everall I. Brown K.P. Moreno P. Verma D. Hill E. Drijkoningen J. Gilligan P. et al Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium Science 2016 354 751 75710.1126/science.aaf8156514260327846606Search in Google Scholar

[47]Chin K.L., Sarmiento M.E., Alvarez-Cabrera N., Norazmi M.N., Acosta A.: Pulmonary non-tuberculous mycobacterial infections: Current state and future management. Eur. J. Clin. Microbiol. Infect. Dis., 2020; 39: 799-826 Chin K.L. Sarmiento M.E. Alvarez-Cabrera N. Norazmi M.N. Acosta A. Pulmonary non-tuberculous mycobacterial infections: Current state and future management Eur. J. Clin. Microbiol. Infect. Dis 2020 39 799 82610.1007/s10096-019-03771-0722204431853742Search in Google Scholar

[48]Jeon D.: Infection source and epidemiology of nontuberculous mycobacterial lung disease. Tuberc. Respir. Dis., 2019; 82: 94-101 Jeon D. Infection source and epidemiology of nontuberculous mycobacterial lung disease Tuberc. Respir. Dis 2019 82 94 10110.4046/trd.2018.0026643593330302953Search in Google Scholar

[49]Axson E.L., Bual N., Bloom C.I., Quint J.K.: Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK. Eur. J. Clin. Microbiol. Infect. Dis., 2019; 38: 117-124 Axson E.L. Bual N. Bloom C.I. Quint J.K. Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK Eur. J. Clin. Microbiol. Infect. Dis 2019 38 117 12410.1007/s10096-018-3402-8631500930368738Search in Google Scholar

[50]Mortaz E., Moloudizargari M., Varahram M., Movassaghi M., Garssen J., Kazempour Dizagie M., Mirsaeidi M., Adcock I.M.: What immunological defects predispose to non-tuberculosis mycobacterial infections? Iran. J. Allergy Asthma Immunol., 2018; 17: 100-109 Mortaz E. Moloudizargari M. Varahram M. Movassaghi M. Garssen J. Kazempour Dizagie M. Mirsaeidi M. Adcock I.M. What immunological defects predispose to non-tuberculosis mycobacterial infections? Iran J. Allergy Asthma Immunol 2018 17 100 109Search in Google Scholar

[51]Bhatt S.P., Nanda S., Kintzer J.S.Jr.: The Lady Windermere syndrome. Prim. Care Respir. J., 2009; 18: 334-336 Bhatt S.P. Nanda S. Kintzer J.S.Jr. The Lady Windermere syndrome Prim. Care Respir. J 2009 18 334 33610.4104/pcrj.2009.00019661935419455268Search in Google Scholar

[52]Holt M.R., Kasperbauer S.H., Koelsch T.L., Daley C.L.: Similar characteristics of nontuberculous mycobacterial pulmonary disease in men and women. Eur. Respir. J., 2019; 54: 1900252 Holt M.R. Kasperbauer S.H. Koelsch T.L. Daley C.L. Similar characteristics of nontuberculous mycobacterial pulmonary disease in men and women Eur. Respir. J 2019 54 190025210.1183/13993003.00252-201930956208Search in Google Scholar

[53]Liao T.L., Lin C.F., Chen Y.M., Liu H.J., Chen D.Y.: Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: A case-control study in a TB endemic area. Sci. Rep., 2016; 6: 29443 Liao T.L. Lin C.F. Chen Y.M. Liu H.J. Chen D.Y. Risk factors and outcomes of nontuberculous mycobacterial disease among rheumatoid arthritis patients: A case-control study in a TB endemic area Sci. Rep 2016 6 2944310.1038/srep29443494140227404002Search in Google Scholar

[54]Mirsaeidi M., Sadikot R.T.: Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis. Int. J. Mycobacteriol., 2015; 4: 92-96 Mirsaeidi M. Sadikot R.T. Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis Int. J. Mycobacteriol 2015 4 92 9610.1016/j.ijmyco.2015.05.002447030326097805Search in Google Scholar

[55]Daley C.L., Iaccarino J.M.Jr., Lange C., Cambau E., Wallace R.J., Andrejak C., Böttger E.C., Brozek J., Griffith D.E., Guglielmetti L., et al.: Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin. Infect. Dis., 2020; 71: 905-913 Daley C.L. Iaccarino J.M.Jr. Lange C. Cambau E. Wallace R.J. Andrejak C. Böttger E.C. Brozek J. Griffith D.E. Guglielmetti L. et al Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline Clin. Infect. Dis 2020 71 905 91310.1093/cid/ciaa1125776874532797222Search in Google Scholar

[56]Haworth C.S., Banks J., Capstick T., Fisher A.J., Gorsuch T., Laurenson I.F., Leitch A., Loebinger M.R., Milburn H.J., Nightingale M., et al.: British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017; 72: ii1-ii64 Haworth C.S. Banks J. Capstick T. Fisher A.J. Gorsuch T. Laurenson I.F. Leitch A. Loebinger M.R. Milburn H.J. Nightingale M. et al British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) Thorax 2017 72 ii1 ii6410.1136/thoraxjnl-2017-21092729054853Search in Google Scholar

[57]Schoenfeld N., Haas W., Richter E., Bauer T., Boes L., Castell S., Hauer B., Magdorf K., Matthiessen W., Mauch H., et al.: Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of non-tuberculous mycobacterioses. Pneumologie, 2016; 70: 250-276 Schoenfeld N. Haas W. Richter E. Bauer T. Boes L. Castell S. Hauer B. Magdorf K. Matthiessen W. Mauch H. et al Recommendations of the German Central Committee against Tuberculosis (DZK) and the German Respiratory Society (DGP) for the diagnosis and treatment of non-tuberculous mycobacterioses Pneumologie 2016 70 250 27610.1055/s-0041-11149427064418Search in Google Scholar

[58]Forbes B.A., Hall G.S., Miller M.B., Novak S.M., Rowlinson M.C., Salfinger M., Somoskövi A., Warshauer D.M., Wilson M.L.: Practical guidance for clinical microbiology laboratories: Mycobacteria. Clin. Microbiol. Reviews, 2018; 31: e00038-17 Forbes B.A. Hall G.S. Miller M.B. Novak S.M. Rowlinson M.C. Salfinger M. Somoskövi A. Warshauer D.M. Wilson M.L. Practical guidance for clinical microbiology laboratories: Mycobacteria Clin. Microbiol. Reviews 2018 31 e00038 1710.1128/CMR.00038-17596769129386234Search in Google Scholar

[59]Stephenson D., Perry A., Appleby M.R., Lee D., Davison J., Johnston A., Jones A.L., Nelson A., Bourke S.J., Thomas M.F., et al.: An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation. BMC Pulm. Med., 2019; 19: 19 Stephenson D. Perry A. Appleby M.R. Lee D. Davison J. Johnston A. Jones A.L. Nelson A. Bourke S.J. Thomas M.F. et al An evaluation of methods for the isolation of nontuberculous mycobacteria from patients with cystic fibrosis, bronchiectasis and patients assessed for lung transplantation BMC Pulm. Med 2019 19 1910.1186/s12890-019-0781-2634153830665395Search in Google Scholar

[60]Minnikin D.E., Minnikin S.M., Parlett J.H., Goodfellow M., Magnusson M.: Mycolic acid patterns of some species of Mycobacterium. Arch. Microbiol., 1984; 139: 225-231 Minnikin D.E. Minnikin S.M. Parlett J.H. Goodfellow M. Magnusson M. Mycolic acid patterns of some species of Mycobacterium. Arch Microbiol 1984 139 225 23110.1007/BF00402005Search in Google Scholar

[61]Kellogg J.A., Bankert D.A., Withers G.S., Sweimler W., Kiehn T.E., Pfyffer G.E.: Application of the Sherlock Mycobacteria identification system using high-performance liquid chromatography in a clinical laboratory. J. Clin. Microbiol., 2001; 39: 964-970 Kellogg J.A. Bankert D.A. Withers G.S. Sweimler W. Kiehn T.E. Pfyffer G.E. Application of the Sherlock Mycobacteria identification system using high-performance liquid chromatography in a clinical laboratory J. Clin. Microbiol 2001 39 964 97010.1128/JCM.39.3.964-970.20018785811230412Search in Google Scholar

[62]Sharma B., Pal N., Malhotra B., Vyas L.: Evaluation of a rapid differentiation test for Mycobacterium tuberculosis from other Mycobacteria by selective inhibition with p-nitrobenzoic acid using MGIT 960. J. Lab. Physicians, 2010; 2: 89-92 Sharma B. Pal N. Malhotra B. Vyas L. Evaluation of a rapid differentiation test for Mycobacterium tuberculosis from other Mycobacteria by selective inhibition with p-nitrobenzoic acid using MGIT 960 J. Lab. Physicians 2010 2 89 9210.4103/0974-2727.72157304008121346904Search in Google Scholar

[63]Huh H.J., Kim S.Y., Jhun B.W., Shin S.J., Koh W.J.: Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases. Infect. Genet. Evol., 2019; 72: 169-182 Huh H.J. Kim S.Y. Jhun B.W. Shin S.J. Koh W.J. Recent advances in molecular diagnostics and understanding mechanisms of drug resistance in nontuberculous mycobacterial diseases Infect. Genet. Evol 2019 72 169 18210.1016/j.meegid.2018.10.00330315892Search in Google Scholar

[64]Tortoli E., Mariottini A., Mazzarelli G.: Evaluation of INNO-LiPA MYCOBACTERIA v2: Improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J. Clin. Microbiol., 2003; 41: 4418-4420 Tortoli E. Mariottini A. Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: Improved reverse hybridization multiple DNA probe assay for mycobacterial identification J. Clin. Microbiol 2003 41 4418 442010.1128/JCM.41.9.4418-4420.200319380312958281Search in Google Scholar

[65]Mok S., Hannan M.M., Nölke L., Stapleton P., O’Sullivan N., Murphy P., McLaughlin A.M., McNamara E., Fitzgibbon M.M., Rogers T.R.: Antimicrobial susceptibility of clinical and environmental Mycobacterium chimaera isolates. Antimicrob. Agents Chemother., 2019; 63: e00755-19 Mok S. Hannan M.M. Nölke L. Stapleton P. O’Sullivan N. Murphy P. McLaughlin A.M. McNamara E. Fitzgibbon M.M. Rogers T.R. Antimicrobial susceptibility of clinical and environmental Mycobacterium chimaera isolates Antimicrob. Agents Chemother 2019 63 e00755 1910.1128/AAC.00755-19670949431262760Search in Google Scholar

[66]de Zwaan R., van Ingen J., van Soolingen D.: Utility of rpoB gene sequencing for identification of nontuberculous mycobacteria in the Netherlands. J. Clin. Microbiol., 2014; 52: 2544-2551 de Zwaan R. van Ingen J. van Soolingen D. Utility of rpoB gene sequencing for identification of nontuberculous mycobacteria in the Netherlands J. Clin. Microbiol 2014 52 2544 255110.1128/JCM.00233-14409768024808238Search in Google Scholar

[67]El Khéchine A., Couderc C., Flaudrops C., Raoult D., Drancourt M.: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice. PLoS One, 2011; 6: e24720 El Khéchine A. Couderc C. Flaudrops C. Raoult D. Drancourt M. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of mycobacteria in routine clinical practice PLoS One 2011 6 e2472010.1371/journal.pone.0024720317229321935444Search in Google Scholar

[68]Saleeb P.G., Drake S.K., Murray P.R., Zelazny A.M.: Identification of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol., 2011; 49: 1790-1794 Saleeb P.G. Drake S.K. Murray P.R. Zelazny A.M. Identification of mycobacteria in solid-culture media by matrix-assisted laser desorption ionization-time of flight mass spectrometry J. Clin. Microbiol 2011 49 1790 179410.1128/JCM.02135-10312264721411597Search in Google Scholar

[69]Rodriguez-Temporal D., Perez-Risco D., Struzka E.A., Mas M., Alcaide F.: Evaluation of two protein extraction protocols based on freezing and mechanical disruption for identifying nontuberculous mycobacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry from liquid and solid cultures. J. Clin. Microbiol., 2018; 56: e01548-17 Rodriguez-Temporal D. Perez-Risco D. Struzka E.A. Mas M. Alcaide F. Evaluation of two protein extraction protocols based on freezing and mechanical disruption for identifying nontuberculous mycobacteria by matrix-assisted laser desorption ionization-time of flight mass spectrometry from liquid and solid cultures J. Clin. Microbiol 2018 56 e01548 1710.1128/JCM.01548-17586984629367300Search in Google Scholar

[70]Cao Y., Wang L., Ma P., Fan W., Gu B., Ju S.: Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of mycobacteria: A systematic review and meta-analysis. Sci. Rep., 2018; 8: 4131 Cao Y. Wang L. Ma P. Fan W. Gu B. Ju S. Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of mycobacteria: A systematic review and meta-analysis Sci. Rep 2018 8 413110.1038/s41598-018-22642-w584135729515167Search in Google Scholar

[71]Brown-Elliott B.A., Fritsche T.R., Olson B.J., Vasireddy S., Vasireddy R., Iakhiaeva E., Alame D., Wallace R.J., Branda J.A.: Comparison of two commercial matrix-assisted laser desorption/ ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for identification of nontuberculous mycobacteria. Am. J. Clin. Pathol., 2019; 152: 527-536 Brown-Elliott B.A. Fritsche T.R. Olson B.J. Vasireddy S. Vasireddy R. Iakhiaeva E. Alame D. Wallace R.J. Branda J.A. Comparison of two commercial matrix-assisted laser desorption/ ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for identification of nontuberculous mycobacteria Am. J. Clin. Pathol 2019 152 527 53610.1093/ajcp/aqz073673335431314059Search in Google Scholar

[72]Brown-Elliott B.A., Nash K.A., Wallace R.J.Jr.: Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin. Microbiol. Rev., 2012; 25: 545-582 Brown-Elliott B.A. Nash K.A. Wallace R.J.Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria Clin. Microbiol. Rev 2012 25 545 58210.1128/CMR.05030-11341648622763637Search in Google Scholar

[73]Pranada A.B., Witt E., Bienia M., Kostrzewa M., Timke M.: Accurate differentiation of Mycobacterium chimaera from Mycobacterium intracellulare by MALDI-TOF MS analysis. J. Med. Microbiol., 2017; 66: 670-677 Pranada A.B. Witt E. Bienia M. Kostrzewa M. Timke M. Accurate differentiation of Mycobacterium chimaera from Mycobacterium intracellulare by MALDI-TOF MS analysis J. Med. Microbiol 2017 66 670 67710.1099/jmm.0.00046928504926Search in Google Scholar

[74]Murugaiyan J., Lewin A., Kamal E., Bakuła Z., van Ingen J., Ulmann V., Unzaga Barañano M.J., Humięcka J., Safianowska A., Roesler U.H., Jagielski T.: MALDI spectra database for rapid discrimination and subtyping of Mycobacterium kansasii. Front. Microbiol., 2018; 9: 587 Murugaiyan J. Lewin A. Kamal E. Bakuła Z. van Ingen J. Ulmann V. Unzaga Barañano M.J. Humięcka J. Safianowska A. Roesler U.H. Jagielski T. MALDI spectra database for rapid discrimination and subtyping of Mycobacterium kansasii. Front Microbiol 2018 9 58710.3389/fmicb.2018.00587Search in Google Scholar

[75]Larrouy-Maumus G., Puzo G.: Mycobacterial envelope lipids fingerprint from direct MALDI-TOF MS analysis of intact bacilli. Tuberculosis, 2015; 95: 75-85 Larrouy-Maumus G. Puzo G. Mycobacterial envelope lipids fingerprint from direct MALDI-TOF MS analysis of intact bacilli Tuberculosis 2015 95 75 8510.1016/j.tube.2014.11.00125488848Search in Google Scholar

[76]Cowman S., van Ingen J., Griffith D.E., Loebinger M.R.: Nontuberculous mycobacterial pulmonary disease. Eur. Respir. J., 2019; 54: 1900250 Cowman S. van Ingen J. Griffith D.E. Loebinger M.R. Nontuberculous mycobacterial pulmonary disease Eur. Respir. J 2019 54 190025010.1097/CPM.0000000000000079Search in Google Scholar

[77]Chau T., Blade K., Da Silva J., Ghaffari A., Zelazny A., Olivier K.: High efficacy of high-dose nitric oxide and its synergistic effect with antibiotics against Mycobacterium abscessus. Eur. Respir. J., 2019; 54: OA4950 Chau T. Blade K. Da Silva J. Ghaffari A. Zelazny A. Olivier K. High efficacy of high-dose nitric oxide and its synergistic effect with antibiotics against Mycobacterium abscessus. Eur Respir. J 2019 54 OA495010.1183/13993003.congress-2019.OA4950Search in Google Scholar

[78]Kendall B.A., Winthrop K.L.: Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin. Respir. Crit. Care Med., 2013; 34: 87-94 Kendall B.A. Winthrop K.L. Update on the epidemiology of pulmonary nontuberculous mycobacterial infections Semin. Respir. Crit. Care Med 2013 34 87 9410.1055/s-0033-133356723460008Search in Google Scholar

[79]Ryu Y.J., Koh W.J., Daley C.L.: Diagnosis and treatment of non-tuberculous mycobacterial lung disease: Clinicians’ perspectives. Tuberc. Respir. Dis., 2016; 79: 74-84 Ryu Y.J. Koh W.J. Daley C.L. Diagnosis and treatment of non-tuberculous mycobacterial lung disease: Clinicians’ perspectives Tuberc. Respir. Dis 2016 79 74 8410.4046/trd.2016.79.2.74482318727066084Search in Google Scholar

[80]Woods G.L., Brown-Elliott B.A., Conville P.S., Desmond E.P., Hall G.S., Lin G., Pfyffer G.E., Ridderhof J.C., Siddiqi S.H., Wallace R.J. Jr., et al.: Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes [Internet]. 2nd ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2011 Mar. Report No.: M24-A2 Woods G.L. Brown-Elliott B.A. Conville P.S. Desmond E.P. Hall G.S. Lin G. Pfyffer G.E. Ridderhof J.C. Siddiqi S.H. Wallace R.J. Jr. et al Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes [Internet]. 2nd ed Wayne (PA) Clinical and Laboratory Standards Institute 2011 Mar. Report No.: M24-A2Search in Google Scholar

[81]Wassilew N., Hoffmann H., Andrejak C., Lange C.: Pulmonary disease caused by non-tuberculous mycobacteria. Respiration, 2016; 91: 386-402 Wassilew N. Hoffmann H. Andrejak C. Lange C. Pulmonary disease caused by non-tuberculous mycobacteria Respiration 2016 91 386 40210.1159/00044590627207809Search in Google Scholar

[82]Wallace R.J.Jr., Brown-Elliott B.A., McNulty S., Philley J.V., Killingley J., Wilson R.W., York D.S., Shepherd S., Griffith D.E.: Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest, 2014; 146: 276-282 Wallace R.J.Jr. Brown-Elliott B.A. McNulty S. Philley J.V. Killingley J. Wilson R.W. York D.S. Shepherd S. Griffith D.E. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease Chest 2014 146 276 28210.1378/chest.13-2538469408224457542Search in Google Scholar

[83]Zweijpfenning S., Kops S., Magis-Escurra C., Boeree M.J., van Ingen J., Hoefsloot W.: Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. Respir. Med., 2017; 131: 220-224 Zweijpfenning S. Kops S. Magis-Escurra C. Boeree M.J. van Ingen J. Hoefsloot W. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort Respir. Med 2017 131 220 22410.1016/j.rmed.2017.08.03128947034Search in Google Scholar

[84]Jarand J., Levin A., Zhang L., Huitt G., Mitchell J.D., Daley C.L.: Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin. Infect. Dis., 2011; 52: 565-571 Jarand J. Levin A. Zhang L. Huitt G. Mitchell J.D. Daley C.L. Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease Clin. Infect. Dis 2011 52 565 57110.1093/cid/ciq23721292659Search in Google Scholar

[85]Koh W.J., Jeong B.H., Kim S.Y., Jeon K., Park K.U., Jhun B.W., Lee H., Park H.Y., Kim D.H., Huh H.J., et al.: Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease. Clin. Infect. Dis., 2017; 64: 309-316 Koh W.J. Jeong B.H. Kim S.Y. Jeon K. Park K.U. Jhun B.W. Lee H. Park H.Y. Kim D.H. Huh H.J. et al Mycobacterial characteristics and treatment outcomes in Mycobacterium abscessus lung disease Clin. Infect. Dis 2017 64 309 31610.1093/cid/ciw72428011608Search in Google Scholar

[86]Boyle D.P., Zembower T.R., Qi C.: Relapse versus reinfection of Mycobacterium avium complex pulmonary disease. Patient characteristics and macrolide susceptibility. Ann. Am. Thorac Soc., 2016; 13: 1956-1961 Boyle D.P. Zembower T.R. Qi C. Relapse versus reinfection of Mycobacterium avium complex pulmonary disease Patient characteristics and macrolide susceptibility. Ann. Am. Thorac Soc 2016 13 1956 196110.1513/AnnalsATS.201605-344BC27599038Search in Google Scholar

[87]Lee B.Y., Kim S., Hong Y., Lee S.D., Kim W.S., Kim D.S., Shim T.S., Jo K.W.: Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease. Antimicrob. Agents Chemother., 2015; 59: 2972-2977 Lee B.Y. Kim S. Hong Y. Lee S.D. Kim W.S. Kim D.S. Shim T.S. Jo K.W. Risk factors for recurrence after successful treatment of Mycobacterium avium complex lung disease Antimicrob. Agents Chemother 2015 59 2972 297710.1128/AAC.04577-14443220125753634Search in Google Scholar

[88]Nessar R., Cambau E., Reyrat J.M., Murray A., Gicquel B.: Mycobacterium abscessus A new antibiotic nightmare. J. Antimicrob. Chemother., 2012; 67: 810-818 Nessar R. Cambau E. Reyrat J.M. Murray A. Gicquel B. Mycobacterium abscessus A new antibiotic nightmare J. Antimicrob. Chemother 2012 67 810 81810.1093/jac/dkr57822290346Search in Google Scholar

[89]van Ingen J., Boeree M.J., van Soolingen D., Mouton J.W.: Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. Drug Resist. Updat., 2012; 15: 149-161 van Ingen J. Boeree M.J. van Soolingen D. Mouton J.W. Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria Drug Resist. Updat 2012 15 149 16110.1016/j.drup.2012.04.00122525524Search in Google Scholar

[90]Guillemin I., Jarlier V., Cambau E.: Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob. Agents Chemother., 1998; 42: 2084-2088 Guillemin I. Jarlier V. Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria Antimicrob. Agents Chemother 1998 42 2084 208810.1128/AAC.42.8.20841058669687411Search in Google Scholar

[91]Alcaide F., Pfyffer G.E., Telenti A.: Role of embB in natural and acquired resistance to ethambutol in mycobacteria. Antimicrob. Agents Chemother., 1997; 41: 2270-2273 Alcaide F. Pfyffer G.E. Telenti A. Role of embB in natural and acquired resistance to ethambutol in mycobacteria Antimicrob. Agents Chemother 1997 41 2270 227310.1128/AAC.41.10.22701641059333060Search in Google Scholar

[92]Soroka D., Dubée V., Soulier-Escrihuela O., Cuinet G., Hugonnet J.E., Gutmann L., Mainardi J.L., Arthur M.: Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase. J. Antimicrob. Chemother., 2014; 69: 691696 Soroka D. Dubée V. Soulier-Escrihuela O. Cuinet G. Hugonnet J.E. Gutmann L. Mainardi J.L. Arthur M. Characterization of broad-spectrum Mycobacterium abscessus class A β-lactamase J. Antimicrob. Chemother 2014 69 69169610.1093/jac/dkt41024132992Search in Google Scholar

[93]Rominski A., Selchow P., Becker K., Brülle J.K., Dal Molin M., Sander P.: Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes. J. Antimicrob. Chemother., 2017; 72: 2191-2200 Rominski A. Selchow P. Becker K. Brülle J.K. Dal Molin M. Sander P. Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes J. Antimicrob. Chemother 2017 72 2191 220010.1093/jac/dkx12528486671Search in Google Scholar

[94]Rominski A., Roditscheff A., Selchow P., Böttger E.C., Sander P.: Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591. J. Antimicrob. Chemother., 2017; 72: 376-384 Rominski A. Roditscheff A. Selchow P. Böttger E.C. Sander P. Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591 J. Antimicrob. Chemother 2017 72 376 38410.1093/jac/dkw46627999011Search in Google Scholar

[95]Nash K.A., Brown-Elliott B.A., Wallace R.J.Jr.: A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob. Agents Chemother., 2009; 53: 1367-1376 Nash K.A. Brown-Elliott B.A. Wallace R.J.Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009 53 1367 137610.1128/AAC.01275-08266306619171799Search in Google Scholar

[96]Meier A., Heifets L., Wallace R.J.Jr., Zhang Y., Brown B.A., Sander P., Böttger E.C.: Molecular mechanisms of clarithromycin resistance in Mycobacterium avium Observation of multiple 23S rDNA mutations in a clonal population. J. Infect. Dis., 1996; 174: 354-360 Meier A. Heifets L. Wallace R.J.Jr. Zhang Y. Brown B.A. Sander P. Böttger E.C. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium Observation of multiple 23S rDNA mutations in a clonal population J. Infect. Dis 1996 174 354 36010.1093/infdis/174.2.3548699066Search in Google Scholar

[97]Prammananan T., Sander P., Brown B.A., Frischkorn K., Onyi G.O., Zhang Y., Böttger E.C., Wallace R.J.Jr.: A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2_‐deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. J. Infect. Dis., 1998; 177: 1573-1581 Prammananan T. Sander P. Brown B.A. Frischkorn K. Onyi G.O. Zhang Y. Böttger E.C. Wallace R.J.Jr. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2_‐deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae J. Infect. Dis 1998 177 1573 158110.1086/5153289607835Search in Google Scholar

[98]Gutsmann T.: Interaction between antimicrobial peptides and mycobacteria. Biochim. Biophys. Acta, 2016; 1858: 1034-1043 Gutsmann T. Interaction between antimicrobial peptides and mycobacteria Biochim. Biophys. Acta 2016 1858 1034 104310.1016/j.bbamem.2016.01.03126851776Search in Google Scholar

[99]Bento C.M., Gomes M.S., Silva T.: Looking beyond typical treatments for atypical mycobacteria. Antibiotics, 2020; 9: 18 Bento C.M. Gomes M.S. Silva T. Looking beyond typical treatments for atypical mycobacteria Antibiotics 2020 9 1810.3390/antibiotics9010018716825731947883Search in Google Scholar

[100]Mohanty S., Jena P., Mehta R., Pati R., Banerjee B., Patil S., Sonawane A.: Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages. Antimicrob. Agents Chemother., 2013; 57: 3688-3698 Mohanty S. Jena P. Mehta R. Pati R. Banerjee B. Patil S. Sonawane A. Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages Antimicrob. Agents Chemother 2013 57 3688 369810.1128/AAC.02475-12371978023689720Search in Google Scholar

[101]Dąbrowska K., Abedon S.T.: Pharmacologically aware phage therapy: Pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies. Microbiol. Mol. Biol. Rev., 2019; 83: e00012-19 Dąbrowska K. Abedon S.T. Pharmacologically aware phage therapy: Pharmacodynamic and pharmacokinetic obstacles to phage antibacterial action in animal and human bodies Microbiol. Mol. Biol. Rev 2019 83 e00012 1910.1128/MMBR.00012-19682299031666296Search in Google Scholar

[102]Górski A., Międzybrodzki R., Łobocka M., Głowacka-Rutkowska A., Bednarek A., Borysowski J., Jończyk-Matysiak E., Łusiak-Szelachowska M., Weber-Dąbrowska B., Bagińska N., et al.: Phage therapy: What have we learned? Viruses, 2018; 10: 288 Górski A. Międzybrodzki R. Łobocka M. Głowacka-Rutkowska A. Bednarek A. Borysowski J. Jończyk-Matysiak E. Łusiak-Szelachowska M. Weber-Dąbrowska B. Bagińska N. et al Phage therapy: What have we learned? Viruses 2018 10 28810.3390/v10060288602484429843391Search in Google Scholar

[103]Azimi T., Mosadegh M., Nasiri M.J., Sabour S., Karimaei S., Nasser A.: Phage therapy as a renewed therapeutic approach to mycobacterial infections: A comprehensive review. Infect. Drug Resist., 2019; 12: 2943-2959 Azimi T. Mosadegh M. Nasiri M.J. Sabour S. Karimaei S. Nasser A. Phage therapy as a renewed therapeutic approach to mycobacterial infections: A comprehensive review Infect. Drug Resist 2019 12 2943 295910.2147/IDR.S218638675657731571947Search in Google Scholar

[104]Dedrick R.M., Guerrero-Bustamante C.A., Garlena R.A., Russell D.A., Ford K., Harris K., Gilmour K.C., Soothill J., Jacobs-Sera D., Schooley R.T., et al.: Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat. Med., 2019; 25: 730-733 Dedrick R.M. Guerrero-Bustamante C.A. Garlena R.A. Russell D.A. Ford K. Harris K. Gilmour K.C. Soothill J. Jacobs-Sera D. Schooley R.T. et al Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus Nat. Med 2019 25 730 73310.1038/s41591-019-0437-z655743931068712Search in Google Scholar

[105]Kelley V.A., Schorey J.S.: Mycobacterium’s arrest of phagosome maturation in macrophages requires Rab5 activity and accessibility to iron. Mol. Biol. Cell, 2003; 14: 3366-3377 Kelley V.A. Schorey J.S. Mycobacterium’s arrest of phagosome maturation in macrophages requires Rab5 activity and accessibility to iron Mol. Biol. Cell 2003 14 3366 337710.1091/mbc.e02-12-078018157312925769Search in Google Scholar

[106]Olakanmi O., Britigan B.E., Schlesinger L.S.: Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect. Immun., 2000; 68: 5619-5627 Olakanmi O. Britigan B.E. Schlesinger L.S. Gallium disrupts iron metabolism of mycobacteria residing within human macrophages Infect. Immun 2000 68 5619 562710.1128/IAI.68.10.5619-5627.200010151410992462Search in Google Scholar

[107]Abdalla M.Y., Switzer B.L., Goss C.H., Aitken M.L., Singh P.K., Britigan B.E.: Gallium compounds exhibit potential as new therapeutic agents against Mycobacterium abscessus. Antimicrob. Agents Chemother., 2015; 59: 4826-4834 Abdalla M.Y. Switzer B.L. Goss C.H. Aitken M.L. Singh P.K. Britigan B.E. Gallium compounds exhibit potential as new therapeutic agents against Mycobacterium abscessus. Antimicrob Agents Chemother 2015 59 4826 483410.1128/AAC.00331-15450526226033732Search in Google Scholar

[108]Choi S.R., Britigan B.E., Switzer B., Hoke T., Moran D., Narayanasamy P.: In vitro efficacy of free and nanoparticle formulations of gallium(iii) meso-tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and gallium biodistribution in mice. Mol. Pharm., 2018; 15: 1215-1225 Choi S.R. Britigan B.E. Switzer B. Hoke T. Moran D. Narayanasamy P. In vitro efficacy of free and nanoparticle formulations of gallium(iii) meso-tetraphenylporphyrine against Mycobacterium avium and Mycobacterium abscessus and gallium biodistribution in mice Mol. Pharm 2018 15 1215 122510.1021/acs.molpharmaceut.7b0103629421865Search in Google Scholar

[109]Bentur L., Gur M., Ashkenazi M., Livnat-Levanon G., Mizrahi M., Tal A., Ghaffari A., Geffen Y., Aviram M., Efrati O.: Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection. J. Cyst. Fibros., 2020; 19: 225-231 Bentur L. Gur M. Ashkenazi M. Livnat-Levanon G. Mizrahi M. Tal A. Ghaffari A. Geffen Y. Aviram M. Efrati O. Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection J. Cyst. Fibros 2020 19 225 23110.1016/j.jcf.2019.05.00231129068Search in Google Scholar

[110]Yaacoby-Bianu K., Gur M., Toukan Y., Nir V., Hakim F., Geffen Y., Bentur L.: Compassionate nitric oxide adjuvant treatment of persistent mycobacterium infection in cystic fibrosis patients. Pediatr. Infect. Dis. J., 2018; 37: 336-338 Yaacoby-Bianu K. Gur M. Toukan Y. Nir V. Hakim F. Geffen Y. Bentur L. Compassionate nitric oxide adjuvant treatment of persistent mycobacterium infection in cystic fibrosis patients Pediatr. Infect. Dis. J 2018 37 336 33810.1097/INF.000000000000178028885458Search in Google Scholar

[111]Waterer G.: Beyond antibiotics for pulmonary nontuberculous mycobacterial disease. Curr. Opin. Pulm. Med., 2020; 26: 260-266 Waterer G. Beyond antibiotics for pulmonary nontuberculous mycobacterial disease Curr. Opin. Pulm. Med 2020 26 260 26610.1097/MCP.000000000000066532101903Search in Google Scholar

[112]Prevots D.R., Adjemian J., Fernandez A.G., Knowles M.R., Olivier K.N.: Environmental risks for nontuberculous mycobacteria. Individual exposures and climatic factors in the cystic fibrosis population. Ann. Am. Thorac. Soc., 2014; 11: 1032-1038 Prevots D.R. Adjemian J. Fernandez A.G. Knowles M.R. Olivier K.N. Environmental risks for nontuberculous mycobacteria Individual exposures and climatic factors in the cystic fibrosis population. Ann. Am. Thorac. Soc 2014 11 1032 103810.1513/AnnalsATS.201404-184OCSearch in Google Scholar

[113]Zimmermann P., Finn A., Curtis N.: Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. J. Infect. Dis., 2018; 218: 679-687 Zimmermann P. Finn A. Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis J. Infect. Dis 2018 218 679 68710.1093/infdis/jiy20729635431Search in Google Scholar